Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.55 |
| ▸ | PPARA | Q07869 | 10/20 | 0.55 |
| ▸ | PPARD | Q03181 | 10/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065302 | 0.93 | PPARG (0.48) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL4056042 | 0.93 | PPARG (0.49) | PPARGPPARAPPARDMAPTITGB3 | |
| SCHEMBL4389495 | 0.88 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL4061597 | 0.86 | PPARD (0.61) | PPARGPPARAPPARDMAPTSMN1; SMN2 | |
| SCHEMBL4056282 | 0.82 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL4055139 | 0.81 | PPARD (0.41) | PPARGPPARAPPARDMAPTSMN1; SMN2 | |
| SCHEMBL4401435 | 0.79 | PPARG (0.51) | PPARGPPARAPPARDMAPT | |
| SCHEMBL4061841 | 0.79 | PPARD (0.55) | PPARGPPARAPPARD | |
| SCHEMBL4392757 | 0.75 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL14514210 | 0.75 | PLA2G4B (0.48) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666472-B1 | PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | ONO PHARMACEUTICAL CO (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-7560475-B2 | Phenylacetic acid derivative, process for producing the same, and use | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20070105868-A1 | Phenylacetic acid derivative, process for producing the same, and use | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1666472-A1 | PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105868-A1 | Phenylacetic acid derivative, process for producing the same, and use | PPARA, PPARD, PPARG | PPARG 3/4885PPARA 1/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.